Status:
COMPLETED
Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies
Lead Sponsor:
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Conditions:
HBV
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Vaccination coverage against HBV in France is around 30% in the adult population. Treatment with anti-CD20 is associated with a risk of reactivation of hepatitis B or acute or fulminant hepatitis in f...
Detailed Description
An accelerated regimen allows healthy adults to obtain vaccine protection very quickly. The accelerated regimen can also be considered on a case-by-case basis in those adults with neurological patholo...
Eligibility Criteria
Inclusion
- Patients over 18 years old
- Multiple sclerosis or other known neurological disease (group 1), systemic vasculitis (group 2) or autoimmune disease (group 3)
- Decision on treatment with anti-CD20 (rituximab or ocrelizumab)
- Free and informed consent, oral
- Negative hepatitis B serology.
Exclusion
- Previous hepatitis B vaccination
- Major disability
- Pregnancy
Key Trial Info
Start Date :
September 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04519710
Start Date
September 15 2020
End Date
October 15 2023
Last Update
February 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Valérie POURCHER
Paris, Île-de-France Region, France, 75013